|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
National Center for Research Resources (NCRR) Yale University |
|---|---|
| Information provided by: | National Center for Research Resources (NCRR) |
| ClinicalTrials.gov Identifier: | NCT00004325 |
Purpose
OBJECTIVES: I. Investigate the pathobiology of Tourette syndrome and related disorders by measuring various compounds of interest in cerebrospinal fluid, plasma, and urine of patients with Tourette syndrome, obsessive compulsive disorder, and/or chronic tics.
II. Determine the pattern of familial aggregation of Tourette syndrome and obsessive compulsive disorder by systematic assessment of all first-degree family members of patients selected for cerebrospinal fluid studies.
III. Establish the neurochemical and neuropeptide profile associated with the range of expression of the putative Tourette gene expression in adult and adolescent patients.
| Condition |
|---|
|
Tourette Syndrome Obsessive Compulsive Disorder |
| Study Type: | Observational |
| Study Design: | Screening |
| Estimated Enrollment: | 200 |
| Study Start Date: | December 1988 |
PROTOCOL OUTLINE: All patients are screened with a complete physical and neurologic exam, and a semi-structured interview. Patients then receive a comprehensive assessment of systemic disease. Patients and first-degree family members also participate in a genetic study.
Any patient who experiences an unusual exacerbation of symptoms or significant side effects is removed from the study.
Eligibility| Ages Eligible for Study: | 12 Years to 45 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
Diagnostic and Statistical Manual of Mental Disorders IV lifetime diagnosis of 1 or more of the following:
Severely affected adolescents with a score of 3 or greater on the TS-Clinical Global Impression Scale eligible
--Prior/Concurrent Therapy--
At least 1 month since any medication
--Patient Characteristics--
Other:
Contacts and Locations| United States, Connecticut | |
| Yale University School of Medicine | |
| New Haven, Connecticut, United States, 06520-8035 | |
| Study Chair: | James F. Leckman | Yale University |
More Information
| Study ID Numbers: | 199/11866, YALESM-4601 |
| Study First Received: | October 18, 1999 |
| Last Updated: | June 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00004325 History of Changes |
| Health Authority: | United States: Federal Government |
|
Tourette syndrome anxiety disorder disease-related problem/condition neurologic and psychiatric disorders |
obsessive compulsive disorder oncologic disorders rare disease |
|
Ganglion Cysts Basal Ganglia Diseases Rare Diseases Central Nervous System Diseases Tourette Syndrome Tic Disorders Neurodegenerative Diseases Brain Diseases |
Tics Heredodegenerative Disorders, Nervous System Genetic Diseases, Inborn Anxiety Disorders Mental Disorders Movement Disorders Mental Disorders Diagnosed in Childhood Obsessive-Compulsive Disorder |
|
Disease Basal Ganglia Diseases Nervous System Diseases Central Nervous System Diseases Tourette Syndrome Tic Disorders Neurodegenerative Diseases Brain Diseases Heredodegenerative Disorders, Nervous System |
Pathologic Processes Genetic Diseases, Inborn Anxiety Disorders Mental Disorders Movement Disorders Syndrome Mental Disorders Diagnosed in Childhood Obsessive-Compulsive Disorder |